No. 47 Investors

Morgan Cheatham

Partner, Healthcare and Life Sciences, Breyer Capital • United States

Investor backing clinical AI and healthcare data infrastructure.

Share Link copied

The Signal

He leads healthcare and life sciences investing at Breyer Capital, and his clinical training and published work on AI in care delivery make him a trusted voice on how these tools reach the bedside.

Who Morgan Cheatham is

Investor backing clinical AI and healthcare data infrastructure.

He leads healthcare and life sciences investing at Breyer Capital, and his clinical training and published work on AI in care delivery make him a trusted voice on how these tools reach the bedside.

Loading the full dossier

At a glance

Role: Partner, Healthcare and Life Sciences
Organisation: Breyer Capital
Platforms: LinkedIn, X
Based in: United States, North America

Influence Score 86.1editorial estimate, see how it is built

Reach (25% weight)83

Audience size across LinkedIn, X, YouTube, podcasts and newsletters.

Engagement (20% weight)84

How much the audience actually reacts, comments, shares and subscribes.

Credibility (25% weight)91

Clinical, research, operating or investing track record behind the commentary.

Consistency (15% weight)88

Publishing cadence and how reliably they show up with original work.

Industry impact (15% weight)86

Whether decision makers, policy and capital actually move on what they say.

Scores are subjective editorial estimates compiled by our research desk from public profiles and published work. They are opinion, not measurement, and they are not a judgement of any person's character or ability.

Also in Investors

Share Link copied

Did we miss something?

Change, add or remove details on this profile. Our desk reviews every request.

This profile is compiled by our research desk from public sources and is published as editorial commentary. Want a correction, an update, or your profile removed? and see our corrections and removals policy.